Condition
Alzheimer Blood Biomarkers
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Recruiting3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07234695Phase 3Recruiting
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
NCT07265323Not ApplicableRecruiting
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
NCT07146412Not ApplicableRecruiting
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
NCT06304129Not ApplicableNot Yet RecruitingPrimary
Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers
Showing all 4 trials